Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.94)
# 3,127
Out of 4,960 analysts
97
Total ratings
36.71%
Success rate
-7.31%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.31 | +116.45% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $2.12 | +135.85% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.69 | +123.05% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $20.32 | +121.51% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $67.49 | +24.46% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $114.77 | -4.16% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $38.63 | -1.63% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $15.56 | -3.60% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $71.82 | -26.20% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.32 | +331.03% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $37.01 | +89.14% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $1.93 | +3.63% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.83 | +938.25% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $5.69 | +233.92% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.92 | +413.70% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $40.00 | -10.00% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $7.20 | +455.56% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.30 | +21.95% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $10.14 | +245.17% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.89 | +403.92% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.36 | +2,105.88% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.17 | +1,609.40% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $5.09 | +96.46% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.90 | +160.87% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.59 | +1,472.33% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $3.50 | -50.04% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $21.08 | -5.12% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.83 | -18.03% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $7.96 | +2,412.56% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.12 | +391.57% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.29 | +4,551.16% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $3.20 | +462.50% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.31
Upside: +116.45%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $2.12
Upside: +135.85%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.69
Upside: +123.05%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $20.32
Upside: +121.51%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $67.49
Upside: +24.46%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $114.77
Upside: -4.16%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $38.63
Upside: -1.63%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $15.56
Upside: -3.60%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $71.82
Upside: -26.20%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.32
Upside: +331.03%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $37.01
Upside: +89.14%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.93
Upside: +3.63%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.83
Upside: +938.25%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $5.69
Upside: +233.92%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.92
Upside: +413.70%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $40.00
Upside: -10.00%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $7.20
Upside: +455.56%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $12.30
Upside: +21.95%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $10.14
Upside: +245.17%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.89
Upside: +403.92%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.36
Upside: +2,105.88%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.17
Upside: +1,609.40%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $5.09
Upside: +96.46%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $6.90
Upside: +160.87%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.59
Upside: +1,472.33%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $3.50
Upside: -50.04%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $21.08
Upside: -5.12%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.83
Upside: -18.03%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $7.96
Upside: +2,412.56%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $7.12
Upside: +391.57%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.29
Upside: +4,551.16%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $3.20
Upside: +462.50%